SCHEMBL7569863

SCHEMBL7569863

CCOC(=O)c1ccc(C#N)c(-c2cccc3cc4ccccc4cc23)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.46
KDM4E B2RXH2 7/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
MEN1 O00255 4/20 0.44
ALDH1A1 P00352 4/20 0.44
KMT2A Q03164 4/20 0.44
RAB9A P51151 3/20 0.44
HCRTR1 O43613 2/20 0.44
CDC25B P30305 3/20 0.43
CDC25A P30304 1/20 0.43
CDC25C P30307 1/20 0.43
HTT P42858 2/20 0.43
NPC1 O15118 2/20 0.43
HSD17B10 Q99714 2/20 0.43
APAF1 O14727 1/20 0.43
CASP3 P42574 1/20 0.43
CASP6 P55212 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7571218 0.91 CDC25B (0.50) MAPTKDM4ESMN1; SMN2MEN1ALDH1A1
SCHEMBL6985555 0.86 KDM4E (0.49) MAPTKDM4ESMN1; SMN2MEN1ALDH1A1
SCHEMBL7571144 0.82 MAPT (0.47) MAPTKDM4ESMN1; SMN2MEN1ALDH1A1
SCHEMBL6984663 0.81 CACNA1C (0.48) MAPTKDM4ESMN1; SMN2MEN1ALDH1A1
SCHEMBL7571031 0.81 MAPT (0.49) MAPTKDM4ESMN1; SMN2MEN1ALDH1A1
SCHEMBL7575780 0.80 HSD17B2 (0.51) MAPTKDM4ESMN1; SMN2MEN1ALDH1A1
SCHEMBL7571121 0.79 KDM4E (0.50) MAPTKDM4ESMN1; SMN2MEN1ALDH1A1
SCHEMBL6984418 0.79 MAPT (0.47) MAPTKDM4ESMN1; SMN2MEN1ALDH1A1
SCHEMBL7571390 0.79 KDM4E (0.46) MAPTKDM4ESMN1; SMN2MEN1ALDH1A1
SCHEMBL7575014 0.78 KDM4E (0.47) MAPTKDM4ESMN1; SMN2MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors ABBOTT LABORATORIES 2002-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors FNTA, FNTB, SLC10A1 MAPT 1802/4885KDM4E 3715/4885SMN1; SMN2 4187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.